China Biotech (01177): Selective HER2 TKI "Zuaini" Again Obtains Breakthrough Therapy Qualification Recognition from CDE

China Biologic Pharmaceuticals (01177) announced that the selective HER2 tyrosine kinase inhibitor (TKI) "Zuoditini" has once again been granted breakthrough therapy designation by the China National Medical Products Administration Drug Evaluation Center (CDE) for the first-line treatment of unresectable or metastatic non-small cell lung cancer (NSCLC) in adults with HER2 tyrosine kinase domain (TKD) activating mutations.